Cutting edge: Stat6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma

Journal of Immunology

Volumn 165, Issue 11, 2000, Pages 6015-6019

  Ostrand Rosenberg, S ^a   Grusby, M J ^a   Clements, V K ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; STAT4 PROTEIN; STAT6 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNOLOGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; LYMPHOCYTE DIFFERENTIATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

EID: 0034544609     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.11.6015     Document Type: Article

References (29)

1. Jaks and Stats in cytokine signaling
2. The Jak-STAT pathway: Cytokine signalling from the receptor to the nucleus
3. JAK/STAT signaling by cytokine receptors
4. Lack of IL-4-induced Th2 response and IgE class switching in mice with distrupted STAT6 gene
5. STAT6 is required for mediating responses to IL-4 and for the development of Th2 cells
6. Regulation of T helper cell differentiation by STAT molecules
7. Signal transducer and activator of transcription factor 6 (STAT6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production
8. STAT6 regulation of in vivo IL-4 responses
9. STAT6-dependent and -independent pathways for IL-4 production
10. + lymphocytes with a Th2 cytokine profile
11. T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6
12. STAT6 is required for the anti-inflammatory activity of IL-4 in mouse peritoneal macrophages
13. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis
14. Impaired IL-12 responses and enhanced development of Th2 cells in STAT4-deficient mice
15. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (STAT)3 and STAT4
16. A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells
17. + T cell responses: Alternative approaches
18. Th1/Th2 balance in cancer, transplantation and pregnancy
19. Cutting edge: Differentiation of antitumor CTL in vivo requires host expression of Stat1
20. Immunologic targets for the gene therapy of cancer
21. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor
22. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with IL-12 reduces established metastatic disease and stimulates immune effectors and monokine-induced by interferon-γ
23. Cooperativity of SEB superantigen, MHC class II, and CD80 in immunotherapy of advanced metastases in a clinically relevant post-operative breast cancer model
24. MHC class II and B7.1 immunotherapeutic cell-based vaccine reduces spontaneous mammary carcinoma metastases without affecting primary tumor growth
25. Evidence implicating L3T4 in class II MHC antigen reactivity: Monoclonal antibody GK1.5 blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines
26. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell mediated cytolysis in the absence of complement
27. 2microglobulin(-/-) knockout mice contain low levels of CD8+ cytotoxic T lymphocytes that mediate specific tumor rejection
28. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: Heterogeneity in phenotypic stability
29. A novel orthotopic model of breast cancer metastasis to bone